新薬動向：抗感染薬

Abstract

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the anti-infective sector. The report includes unique sales forecasts by major product.

The full 400-page report, evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. The report covers 8 key therapy areas (alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS, musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by major product. Click here for more information. This chapter is available separately.

The anti-infectives market is the fifth largest therapeutic category. We estimate that anti-infectives grossed sales of US$28.5 billion in 2005, with a further US$16 billion being derived from hospital-based use and OTC. The majority of prescription-based sales were derived from the US (around 50%) compared to 22% in Europe and Japan. However, growth in Europe at over 5% exceeded that of the US and Japan compared with around 3%.

Table of Contents

CURRENT MARKET SIZE

• Antibiotic Sales
• Antiviral Sales
• Antifungal Sales

ADDRESSABLE PATIENT POPULATION

• Bacterial Infections
• Viral infections
  • Human Immunodeficiency Virus (HIV)
  • Hepatitis B (HBV)
  • Hepatitis C (HCV)

CURRENT TREATMENTS

• Antibacterial Agents
• Antiviral Agents- HIV
• Antiviral Agents- HCV/HBV

ANTI-INFECTIVES SALES DRIVERS

ANTI-INFECTIVE SALES BREAKERS

FUTURE TREATMENTS

MARKET DYNAMICS - WINNERS & LOSERS

KEY DRUGS LAUNCHES BY 2010

KEY EVALUATION CRITERIA

KEY ANTI-INFECTIVES DRUG LAUNCHES BY 2010

• Anidulafungin (Pfizer)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Aptivus (Boehringer Ingelheim)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Aplaviroc (GlaxoSmithKline)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Ceftobiprole (Johnson & Johnson)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Garenoxicin (Schering-Plough)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• GW695634 (GlaxoSmithKline)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Maraviroc (Pfizer)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• MK-0518 (Merck & Co)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Retapamulin (GlaxoSmithKline)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Telbivudine (Novartis)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management and clinical expertise
  • Competition within the marketplace/ gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings & Approvals
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• TMC-114 (Johnson & Johnson/Tibotec Pharma)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Tygacil (Wyeth)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Vicriviroc (Schering-Plough)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• VX-950 (Vertex Pharmaceuticals)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumption
  • Competitor Ratio Analysis
• Zeven (Pfizer)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis

COMPETITOR RATIO ANALYSIS SUMMARY

COMPETITOR RATIO ANALYSIS - COMPANIES